General clinical characteristics of the six patients with HSV-FVH and AAN-I-IFNs
| Patient | Age | Sex | Virus | FVH outcome | Autoimmune history |
|---|---|---|---|---|---|
| P1 | 18 | F | HSV-2 | Survival | HLA-B27 spondyloenthesoarthritis, seronegative rheumatoid arthritis |
| P2 | 68 | F | HSV-1 | Survival | Arthritis, antinuclear antibodies, anti-smooth muscle antibodies |
| P3 | 21 | F | HSV-1 | Death | Systemic lupus erythematous |
| P4 | 50 | M | HSV-1 | Survival | - |
| P5 | 58 | M | HSV-2 | Survival | - |
| P6 | 18 | F | HSV-2 | Survival | - |
| Patient | Age | Sex | Virus | FVH outcome | Autoimmune history |
|---|---|---|---|---|---|
| P1 | 18 | F | HSV-2 | Survival | HLA-B27 spondyloenthesoarthritis, seronegative rheumatoid arthritis |
| P2 | 68 | F | HSV-1 | Survival | Arthritis, antinuclear antibodies, anti-smooth muscle antibodies |
| P3 | 21 | F | HSV-1 | Death | Systemic lupus erythematous |
| P4 | 50 | M | HSV-1 | Survival | - |
| P5 | 58 | M | HSV-2 | Survival | - |
| P6 | 18 | F | HSV-2 | Survival | - |
Sharing content requires targeting cookies to be enabled. Please update your cookie preferences to use this feature.